Related Experiment Videos
Perinatal cerebral asphyxia: pharmacological intervention
A J Gunn1, C E Williams, L Bennet
1Department of Paediatrics, University of Auckland, New Zealand.
Insights
Flunarizine, a calcium antagonist, shows neuroprotective effects against perinatal asphyxia, reducing risks of cerebral palsy. MK-801, an amino acid antagonist, effectively prevented seizures following ischemic insults in preclinical models.
Area of Science:
- Neuroscience
- Pharmacology
- Perinatal Medicine
Background:
- Perinatal asphyxia poses significant risks for mortality and cerebral palsy.
- Hypoxic-ischemic insults during birth can lead to severe neurological sequelae.
- Novel therapeutic strategies are needed to mitigate the effects of birth asphyxia.
Purpose of the Study:
- To investigate the neuroprotective potential of flunarizine and MK-801 in models of perinatal asphyxia.
- To evaluate the efficacy of these agents in preventing neurological damage and seizures post-insult.
- To explore future therapeutic prospects for managing birth asphyxia complications.
Main Methods:
- Utilized an infant rat model with unilateral carotid ligation and hypoxia to assess flunarizine's neuroprotection.
- Employed a novel fetal sheep model to study the prophylactic effects of flunarizine on cerebral ischemia.
- Administered MK-801 to evaluate its impact on post-ischemic seizures in relevant animal models.
Main Results:
- Flunarizine demonstrated neuroprotective effects in infant rats subjected to hypoxia.
- Prophylactic flunarizine treatment significantly altered outcomes in fetal sheep following total cerebral ischemia.
- MK-801 successfully prevented seizures in the post-ischemic phase.
Conclusions:
- Flunarizine holds promise as a neuroprotective agent for conditions like perinatal asphyxia.
- MK-801 may be beneficial in managing acute seizure complications associated with ischemic brain injury.
- Further research into these pharmacological interventions is warranted for clinical application.
Abstract:
Perinatal asphyxia is associated with an increased risk of cerebral palsy and significant mortality. We investigated the use of flunarizine, a calcium antagonist and MK-801, an excitatory amino acid antagonist, in preventing the sequelae of severe hypoxic/ischemic insults. Flunarizine was neuroprotective in the infant rat subjected to unilateral carotid ligation and 2 h of hypoxia. Preliminary analysis of experiments in a novel model of cerebral ischemia in the fetal sheep suggests that prophylactic treatment with flunarizine greatly modified the outcome after 30 min of total ischemia. Treatment with MK-801 prevented post-ischemic seizures. The background to these developments is outlined and future prospects considered.